Top

Published in:

01-08-2017 | Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Pathophysiology and Current Clinical Management of Preeclampsia

Authors: Lorena M. Amaral, Kedra Wallace, Michelle Owens, Babbette LaMarca

Published in: Current Hypertension Reports | Issue 8/2017

Abstract

Preeclampsia is characterized by blood pressure greater than 140/90 mmHg in the second half of pregnancy. This disease is a major contributor to preterm and low birth weight babies. The early delivery of the baby, which becomes necessary for maintaining maternal well-being, makes preeclampsia the leading cause for preterm labor and infant mortality and morbidity. Currently, there is no cure for this pregnancy disorder. The current clinical management of PE is hydralazine with labetalol and magnesium sulfate to slow disease progression and prevent maternal seizure, and hopefully prolong the pregnancy. This review will highlight factors implicated in the pathophysiology of preeclampsia and current treatments for the management of this disease.

•• American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstetrics and gynecology. 2013;122(5):1122–31. doi:10.1097/01.AOG.0000437382.03963.88. This report highlights recommendations and guidelines for the management of patients with hypertension during and after pregnancy.

Creasy RK, Resnik R, Greene MF, Iams JD, Lockwood CJ. Creasy and Resnik’s maternal-fetal medicine: principles and practice. Seventh edition ed.

Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99(7):547–53.CrossRefPubMed

Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Investig. 1999;103:945–52.CrossRefPubMedPubMedCentral

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7. doi:10.1053/j.semperi.2009.02.010.CrossRefPubMed

Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066–74. doi:10.1016/S0140-6736(06)68397-9.CrossRefPubMed

Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol. 1997;37(3):240–9.CrossRefPubMed

Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294(2):H541–50. doi:10.1152/ajpheart.01113.2007.CrossRefPubMed

Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol. 2010;62(2):105–20.PubMedPubMedCentral

10.

Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res. 2010;36(2):239–47. doi:10.1111/j.1447-0756.2009.01128.x.CrossRefPubMed

11.

Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nat Clin Pract Nephrol. 2005;1(2):98–114; quiz 20. doi:10.1038/ncpneph0035.CrossRefPubMed

12.

Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–4. doi:10.1126/science.1111726.CrossRefPubMed

13.

Sandrim VC, Montenegro MF, Palei AC, Metzger IF, Sertorio JT, Cavalli RC, et al. Increased circulating cell-free hemoglobin levels reduce nitric oxide bioavailability in preeclampsia. Free Radic Biol Med. 2010;49(3):493–500. doi:10.1016/j.freeradbiomed.2010.05.012.CrossRefPubMed

14.

Amaral LM, Palei AC, Sandrim VC, Luizon MR, Cavalli RC, Duarte G, et al. Maternal iNOS genetic polymorphisms and hypertensive disorders of pregnancy. J Hum Hypertens. 2012;26(9):547–52. doi:10.1038/jhh.2011.65.CrossRefPubMed

15.

• Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension. 2005;46(6):1243-9. doi:10.1161/01.HYP.0000188408.49896.c5. The review highlights valuable insights into pathophysiology that could guide ongoing clinical trials.

16.

Granger JP. Inflammatory cytokines, vascular function, and hypertension. American journal of physiology. Regulatory, integrative and comparative physiology. 2004;286(6):R989–90. doi:10.1152/ajpregu.00157.2004.CrossRefPubMed

17.

Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002;9(3):147–60. doi:10.1038/sj.mn.7800137.CrossRefPubMed

18.

Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med. 2006;8(3):1–20. doi:10.1017/S1462399406010465.CrossRefPubMed

19.

Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534–43. doi:10.1111/j.1600-0897.2010.00831.x.CrossRefPubMed

20.

Lamarca B, Cornelius D, Wallace K. Elucidating immune mechanisms causing hypertension during pregnancy. Physiology. 2013;28:225–33.CrossRefPubMedPubMedCentral

21.

Borzychowski A, Sargent I, Redman C. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11(5):309–16.CrossRefPubMed

22.

LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep. 2007;9(6):480–5.CrossRefPubMed

23.

• Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010;55(2):394–8. doi:10.1161/HYPERTENSIONAHA.109.141473. The study shows the important role of sFlt-1 to induce PE-like syndrome through nitric oxide and endothelin-1 pathways.

24.

Murphy SR, LaMarca BB, Parrish M, Cockrell K, Granger JP. Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-alpha. American journal of physiology. Regulatory, integrative and comparative physiology. 2013;304(2):R130–5. doi:10.1152/ajpregu.00069.2012.CrossRefPubMed

25.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58. doi:10.1172/JCI17189.CrossRefPubMedPubMedCentral

26.

Dechend R, Muller D, Wallukat G, Homuth V, Krause M, Dudenhausen J, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol. 2004;24(6):571–9.CrossRefPubMed

27.

•• LaMarca B, Wallace K, Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Current Opinions in Pharmacology. 2011;11(2):175–9. This review discusses the potential role of the AT1-AA in mediating hypertension during pregnancy.

28.

Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, et al. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension. 2004;43(3):614–22. doi:10.1161/01.HYP.0000116220.39793.c9.CrossRefPubMed

29.

Eleuterio NM, Palei AC, Rangel Machado JS, Tanus-Santos JE, Cavalli RC, Sandrim VC. Relationship between adiponectin and nitrite in healthy and preeclampsia pregnancies. Clinica chimica acta; international journal of clinical chemistry. 2013;423:112–5. doi:10.1016/j.cca.2013.04.027.

30.

Sandrim VC, Palei AC, Metzger IF, Cavalli RC, Duarte G, Tanus-Santos JE. Interethnic differences in ADMA concentrations and negative association with nitric oxide formation in preeclampsia. Clinica chimica acta; international journal of clinical chemistry. 2010;411(19–20):1457–60. doi:10.1016/j.cca.2010.05.039.

31.

Murphy SR, LaMarca B, Cockrell K, Arany M, Granger JP. L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. American journal of physiology. Regulatory, integrative and comparative physiology. 2012;302(2):R259–63. doi:10.1152/ajpregu.00319.2011.CrossRefPubMed

32.

Perez-Sepulveda A, Torres M, Khoury M, Illanes S. Innate immune system and preeclampsia. Front Immunol. 2014;5:244.CrossRefPubMedPubMedCentral

33.

Dhillion P, Wallace K, Scott J, Herse F, Heath J, Moseley J, et al. IL-17 mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2012;303(4):R353–R8.CrossRefPubMedPubMedCentral

34.

LaMarca B, Alexander B, Gilbert J, Ryan M, Sedeek M, Murphy S, et al. Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin? Gender Medicine. 2008;5:S133–S8.CrossRefPubMedPubMedCentral

35.

Wallace K, Novotny S, Heath J, Moseley J, Martin J, Owens M, et al. Hypertension in response to CD4+ T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system. Am J Physiol Regul Integr Comp Physiol. 2012;303(2):R144–9.CrossRefPubMedPubMedCentral

36.

Raijmakers M, Dechend R, Poston L. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension. 2004;44:374–80.CrossRefPubMed

37.

Redman C, Sargent I. Placental debris, oxidative stress and pre-eclampsia. Placenta. 2000;21(7):597–602.CrossRefPubMed

38.

Wallace K, Cornelius D, Scott J, Heath J, Moseley J, Chatman K, et al. CD4⁺ T cells are important mediators of oxidative stress that cause hypertension in response to placental ischemia. Hypertension. 2014;64(5):1151–8. doi:10.1161/HYPERTENSIONAHA.114.03590.CrossRefPubMedPubMedCentral

39.

Walsh S. Obesity: a risk factor for preeclampsia. Trends in Endocrinology & Metabolism. 2007;18(10):365–70.CrossRef

40.

Spradley F, Palei A, Granger J. Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms. Am J Physiol Regul Integr Comp Physiol. 2015;309(11):R1326–43.CrossRefPubMedPubMedCentral

41.

Villa P, Marttinen P, Gillberg J, Lokki A, Majander K, Orden M, et al. Cluster analysis to estimate the risk of preeclampsia in the high-risk prediction and prevention of preeclampsia and intrauterine growth restriction (PREDO) study. PLoS One. 2017;12(3):e0174399.CrossRefPubMedPubMedCentral

42.

Bartsch E, Medcalf K, Park A, Ray J, Group HRoP-eI. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753.

43.

Spradley F, Palei A, Granger J. Immune mechanisms linking obesity and preeclampsia. Biomol Ther. 2015;5:3142–76.

44.

Womack J, Tien P, Feldman J, Shin J, Fennie K, Anastos K, et al. Obesity and immune cell counts in women. Metabolism. 2007;56(7):998–1004.CrossRefPubMedPubMedCentral

45.

Aye I, Lager S, Ramirez V, Gaccioli F, Dudley D, Jasson T, et al. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod. 2014;90(6):129.CrossRefPubMedPubMedCentral

46.

Zavalza-Gomez A. Obesity and oxidative stress: a direct link to preeclampsia? Arch Gyneccol Obstet. 2011;283(3):415–22.CrossRef

47.

Saben J, Lindsey F, Zhong Y, Thakali K, Badger T, Andres A, et al. Maternal obesity is associated with a lipotoxic placental environment. Placenta. 2014;35:171–7.CrossRefPubMedPubMedCentral

48.

Costa R, Hoshida M, Alves E, Zugaib M, Francisco R. Preeclampsia and superimposed preeclampsia: the same disease? The role of angiogenic biomarkers. Hypertension in Pregnancy. 2016;35(2):139–49.CrossRefPubMed

49.

Jensen D, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard J, Moeller M, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care. 2004;27(12):2819–23.CrossRefPubMed

50.

Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study. Diabetes Care. 2009;32(11):2005–9.

51.

Knight K, Thornburg L, Pressman E. Pregnancy outcomes in type 2 diabetic patients as compared with type 1 diabetic patients and nondiabetic controls. J Reprod Med. 2012;57(9–10):397–404.PubMed

52.

Groen B, Links T, van den Berg P, Hellinga M, Moerman S, Visser G, et al. Similar adverse pregnancy outcome in native and nonnative Dutch women with pregestational type 2 diabetes: a multicentre retrospective study. ISRN Obstet Gynecol. 2013;2013:361435.CrossRefPubMedPubMedCentral

53.

Weissgerber T, Mudd L. Preeclampsia and diabetes. Curr Diab Rep. 2015;15(3):579.CrossRefPubMedCentral

54.

Nunemaker C. Considerations for defining cytokine dose, duration and milieu that are appropriate for modeling chronic low-grade inflammation in type 2 diabetes. J Diabetes Res. 2016;2016:2846570.CrossRefPubMedPubMedCentral

55.

Scioscia M, Gumaa K, Rademacher T. The link between insulin resistance and preeclampsia: new perspective. J Reprod Immunol. 2009;82(2):100–5.CrossRefPubMed

56.

Guimaraes M, Brandao A, Rezende C, Cabral A, Brum A, Leite H, et al. Assessment of endothelial function in pregnant women with pre-eclampsia and gestational diabetes mellitus by flow-mediated dilation of brachial artery. Arch Gyneccol Obstet. 2014;290(3):441–7.CrossRef

57.

Conti E, Zezza L, Ralli E, Caserta D, Musumeci M, Moscarini M, et al. Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards? Cytokine Growth Factor Rev. 2013;24(5):411–25.CrossRefPubMed

58.

Karacay O, Sepici-Dincel A, Karcaaltincaba D, Sahin D, Yalvac S, Akyol M, et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in preeclampsia and gestational diabetic patients in 24-36 weeks gestation. Diabetes Res Clin Pract. 2010;89(3):231–8.CrossRefPubMed

59.

Clowse M, Jamison M, Myers E, James A. National study of medical complications in SLE pregnancies. Arthritis Rheum. 2006;54(S9):S263.

60.

Clark C, Spitzer K, Nadler J, Laskin C. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol. 2003;30(10):2127–32.PubMed

61.

Emerudh J, Berg G, Mjosberg J. Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance. Am J Reprod Immunol. 2011;66(Suppl 1):31–43.CrossRef

62.

Cornelius D, Amaral L, Harmon A, Wallace K, Thomas A, Campbell N, et al. An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2015;309(8):R884–R91.CrossRefPubMedPubMedCentral

63.

Prins J, Boelens H, Heimweg J, Van der Heide S, Dubois A, Van Oosterhout A, et al. Preeclampsia is associated with lower percentages of regulatory T cells in maternal blood. Hypertension in Pregnancy. 2009;28:300–11.CrossRefPubMed

64.

Gluhovschi C, Gluhovschi G, Petrica L, Velciov S, Gluhovschi A. Pregnancy associated with systemic lupus wrythematosus: immune tolerance in pregnancy and its deficiency in systemic lupus erythematosus—an immunological dilemma. J Immunol Res. 2015;2015(241547).

65.

Ulcova-Gallova Z, Mockova A, Cedikova M. Screening tests of reproductive immunology in systemic lupus erythematosus. Autoimmune Diseases. 2012;2012:812138.CrossRefPubMedPubMedCentral

66.

Hayslett J. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am J Reprod Immunol. 1992;28(3–4):199–204.CrossRefPubMed

67.

• Guillemette L, Lacroix M, Allard C, Patenaude J, Battista M, Doyon M et al. Preeclampsia is associated with an increased pro-inflammatory profile in newborns. J Reprod Immunol. 2015;112:111-4. The study shows that newborns from mothers diagnosed with PE have higher levels of TNFα at birth.

68.

• Nomura Y, John R, Janssen A, Davey C, Finik J, Buthmann J et al. Neurodevelopmental consequences in offspring of mothers with preeclampsia during pregnancy: underlying biological mechanism via imprinting genes. Arch Gyneccol Obstet. 2017;295(6):1319-29. This recent review attempts to show new evidence for imprinting gene dysregulation caused by hypertension and that could explain the link between preeclampsia and neurocognitive problems in offspring.

69.

Too GT, Hill JB. Hypertensive crisis during pregnancy and postpartum period. Semin Perinatol. 2013;37(4):280–7. doi:10.1053/j.semperi.2013.04.007.CrossRefPubMed

70.

•• Owens MY, Martin JN, Jr., Wallace K, Keiser SD, Parrish MR, Tam Tam KB et al. Postpartum thrombotic microangiopathic syndrome. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis. 2013;48(1):51-7. doi:10.1016/j.transci.2012.05.016. This study reports an important patient case and discusses about the early recognition of thrombotic thrombocytopenic purpura for the appropriate treatment.

71.

Committee on Obstetric P. Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol 2015;125(2):521–525. doi:10.1097/01.AOG.0000460762.59152.d7.

Title: Pathophysiology and Current Clinical Management of Preeclampsia
Authors: Lorena M. Amaral
Kedra Wallace
Michelle Owens
Babbette LaMarca
Publication date: 01-08-2017
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 8/2017
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-017-0757-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Pathophysiology and Current Clinical Management of Preeclampsia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

Response to the Letter from Landman et al:

Role of Collecting Duct Renin in the Pathogenesis of Hypertension

Comments on: Cernes, R. & Zimlichman, R. Role of Paced Breathing for Treatment of Hypertension. Curr Hypertens Rep (2017) 19: 45

Molecular Mechanisms of Sodium-Sensitive Hypertension in the Metabolic Syndrome

The Elusive Search for Optimal Blood Pressure Targets

Managing Hypertension in the Elderly: What is Different, What is the Same?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page